Brasília – The board of the Brazilian National Health Surveillance Agency (ANVISA) once again extended the validity of special rules for the import of essential medication in the context of the public health emergency of the COVID-19 pandemic.
Resolution 483, published this year, facilitates importing new medical devices and priority medicines defined by the World Health Organization (WHO) to respond to COVID-19. The regulation waives the requirement of sanitary regularization of the product to be imported on an exceptional basis, maintaining requirements such as guaranteeing quality, safety, and efficacy and monitoring the use of the product in the market.
The CEO of ANVISA, Antônio Barra Torres, highlighted the need to maintain the vaccination campaign and preventive care to restrict the spread of the virus and the propagation of coronavirus cases. “New uncertainties arise, like the Delta variant. We have to maintain the non-pharmacological measures and seek the conviction that vaccination is necessary,” he commented.
Translated by Elúsio Brasileiro
